Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma

Conclusion: 18F-FDG PET metabolic volume response predicts survival in patients with malignant mesothelioma receiving high-dose pembrolizumab. These results should prompt inclusion of PET response assessment in future phase 3 clinical trials.

Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Ferdinandus, J., Barbato, F., Chodyla, M., Fendler, W. P., Kessler, L., Pomykala, K. L., Metzenmacher, M., Krefting, F., Hager, T., Umutlu, L., Herrmann, K., Christoph, D. C. Tags: Clinical Source Type: research